Highlights

  • PYC Therapeutics (ASX:PYC) reported FY26 income from ordinary activities of AUD 39.68mn.
  • The FY26 attributable net loss was AUD 43.34mn, down 13.8% year on year.
  • PYC-003 single-dose kidney disease data showed a 46% rise in urinary PC1 from baseline in treated patients.
  • A Phase 1b multiple-dose study and open-label extension are continuing, with data expected in CY27.

PYC Therapeutics Limited develops investigational RNA medicines for genetic diseases, using a proprietary delivery platform to bring therapeutic molecules into targeted cells. Its recent clinical disclosures focus on PYC-003 for polycystic kidney disease and other programs for inherited disorders affecting vision. On 26 October 2026, PYC Therapeutics (ASX:PYC) was quoted at AUD 1.723, down 3.23% for the session. Its FY26 report and October PYC-003 updates provide a view of trial progress, available funding and the next development milestones.

Company Business

PYC Therapeutics (ASX:PYC) is a clinical-stage biotechnology company headquartered in Western Australia, with activities in Australia and the United States. It develops peptide-conjugated oligonucleotide medicines intended to modify the production of proteins involved in inherited diseases. The delivery technology is designed to improve access of RNA treatments to tissues in which conventional delivery presents difficulties.

Its clinical pipeline includes VP-001 for retinitis pigmentosa type 11, PYC-001 for autosomal dominant optic atrophy and PYC-003 for autosomal dominant polycystic kidney disease. A further program, PYC-002, targets Phelan-McDermid syndrome. These programs are at different development stages, and none of the drug candidates discussed here has received marketing authorisation.

Recent Development

In October 2026, PYC Therapeutics (ASX:PYC) disclosed exploratory findings from the single-ascending-dose portion of its PYC-003 study in patients with polycystic kidney disease. The company reported that urinary polycystin-1, or PC1, a marker of target engagement in the kidney, increased by 46% relative to baseline. Its presentation also examined total kidney volume three months after a single dose. The findings came from a limited number of patients over a short period, and further studies are required to assess durability and clinical effect.

Financial Performance and Sector Context

For FY26, PYC Therapeutics (ASX:PYC) reported income from ordinary activities of AUD 39.68mn, an increase of 51.6% from FY25. Its loss attributable to owners was AUD 43.34mn, declining 13.8% year on year. These results reflect a development-stage business whose financial profile is driven by research expenditure, financing and related non-commercial income rather than sales of approved medicines.

At 30 June 2026, the company reported approximately AUD 696mn across cash, cash equivalents, financial assets and its research-and-development tax incentive receivable. This included AUD 53.6mn in cash and cash equivalents, AUD 350.1mn in term deposits, AUD 265.1mn in financial assets and AUD 25.7mn in an R&D tax incentive receivable. A capital raising completed in early 2026 contributed approximately AUD 600mn before costs and was intended to fund clinical work into CY2030.

The June-quarter Appendix 4C recorded net operating cash inflow of AUD 2.89mn, while FY26 operating cash outflow totalled AUD 44.58mn. Research spending, trial timing and government incentives affect reporting-period cash flows.

Risks to Consider

Clinical outcomes remain uncertain for PYC Therapeutics (ASX:PYC). The reported PC1 and kidney-volume results are exploratory and require confirmation through repeat dosing, larger patient groups and longer observation. Safety, manufacturing scale-up and clinical protocol execution may affect schedules and costs. Although the recent financing expanded available resources, future development expenditure will depend on the progress and design of multiple clinical programs. Regulatory approval is not assured.

What to Watch Next

Upcoming points for PYC Therapeutics (ASX:PYC) include the ongoing Phase 1b multiple-dose and open-label extension work for PYC-003, with clinical updates anticipated in CY27. Investors can also monitor clinical results across VP-001 and PYC-001, the next stage of PYC-002 development, and quarterly cash-flow statements. The company has identified further regulatory alignment as part of the pathway toward a proposed combined Phase 2/3 PYC-003 trial.

Key Insights

PYC Therapeutics (ASX:PYC) ended FY26 with a substantially expanded pool of financial resources following its capital raising, while recording a net loss as research activities continued. October disclosures added exploratory target-engagement observations for PYC-003 and outlined the continuing repeat-dose study. The principal measurable developments are clinical safety and efficacy evidence, planned regulatory discussions and the pace of expenditure across the pipeline.